Publication Name	World Journal of Clinical Cases
Manuscript ID	70373
Country	China

Received	2021-08-09 05:23
Peer-Review Started	2021-08-09 05:27
To Make the First Decision
Return for Revision	2021-11-18 12:32
Revised	2021-12-04 07:13
Second Decision	2022-02-17 05:50
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-02-20 12:57
Articles in Press	2022-02-20 12:57
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-02-02 17:26
Typeset the Manuscript	2022-03-01 03:44
Publish the Manuscript Online	2022-03-22 14:35

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Treatment with sorafenib plus camrelizumab after splenectomy for primary splenic angiosarcoma with liver metastasis: A case report and literature review
Manuscript Source	Unsolicited Manuscript
All Author List	Dan Pan, Tai-Ping Li, Jian-Hui Xiong, Shu-Bo Wang, Yao-Xu Chen, Jian-Feng Li and Qi Xiao
ORCID	Author(s) ORCID Number Dan Pan http://orcid.org/0000-0001-5535-8331 Tai-Ping Li http://orcid.org/0000-0002-3365-2676 Jian-Hui Xiong http://orcid.org/0000-0003-0000-4338 Shu-Bo Wang http://orcid.org/0000-0003-2470-7214 Yao-Xu Chen http://orcid.org/0000-0002-8850-4267 Jian-Feng Li http://orcid.org/0000-0001-9426-2842 Qi Xiao http://orcid.org/0000-0002-3849-2755
Funding Agency and Grant Number	Funding Agency Grant Number Natural Science Foundation of Jiangxi Province 20192BAB215012, 20212BAB206027 Health Commission of Jiangxi Province 20203206
Corresponding Author	Qi Xiao, PhD, Chief Doctor, Department of General Surgery, The First Affiliated Hospital of Nanchang University, No.17 Yongwai Zheng Road, Donghu District, Nanchang 330006, Jiangxi Province, China. xiaoqidoctor@163.com
Key Words	Primary splenic angiosarcoma; Immunotherapy; Targeted therapy; Prognosis; Case report
Core Tip	Splenectomy is the preferred treatment for primary splenic angiosarcoma (PSA); however, PSA patients may experience a good or poor prognosis after splenectomy. Although the prognosis in patients with liver metastases or rupture of the spleen is extremely poor, immunotherapy or targeted therapy has not been attempted after surgery. This case is the first report of a PSA patient with liver metastasis and splenic rupture, receiving sorafenib plus camrelizumab as adjuvant therapy. After 15 mo of follow-up, the patient is in good condition without recurrence or identified metastasis. Apart from chemotherapy and radiotherapy, targeted therapies and immunotherapy may also be an option for adjuvant therapy.
Publish Date	2022-03-22 14:35
Citation	Pan D, Li TP, Xiong JH, Wang SB, Chen YX, Li JF, Xiao Q. Treatment with sorafenib plus camrelizumab after splenectomy for primary splenic angiosarcoma with liver metastasis: A case report and literature review. World J Clin Cases 2022; 10(9): 2818-2828
URL	https://www.wjgnet.com/2307-8960/full/v10/i9/2818.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i9.2818

Full Article (PDF)	WJCC-10-2818.pdf
Full Article (Word)	WJCC-10-2818.docx
CARE Checklist–2016	70373-CARE-Checklist–2016-revision.pdf
Manuscript File	70373_Auto_Edited-JJW-Webster J.docx
Answering Reviewers	70373-Answering reviewers.pdf
Audio Core Tip	70373-Audio core tip.aac
Conflict-of-Interest Disclosure Form	70373-Conflict-of-interest statement.pdf
Copyright License Agreement	70373-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	70373-Grant application form(s).pdf
Signed Consent for Treatment Form(s) or Document(s)	70373-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	70373-Language certificate.pdf
Peer-review Report	70373-Peer-review(s).pdf
Scientific Misconduct Check	70373-Bing-Wang JJ-2.png
Scientific Editor Work List	70373-Scientific editor work list.pdf
CrossCheck Report	70373-CrossCheck report.pdf